I receive this question a lot. We certainly don’t recommend it on the front-end, but if patients wish to take them, we allow it.
We are still administering ipilimumab over 90 min and nivolumab over 60 min. However, I believe that we are in the process of changing the infusion time for nivolumab to 30 minutes across the institution.
Xerostomia (from Sjogren’s as an immune adverse event) can certainly set people up for decay and other dental issues.
